Evogene (NASDAQ: EVGN) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.27) by 122.22 percent. This is a 57.89 percent decrease over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $334.000 thousand which missed the analyst consensus estimate of $350.000 thousand by 4.57 percent. This is a 86.33 percent decrease over sales of $2.444 million the same period last year.